typical semaglutide results Weight Loss Results: What to Expect The Pros and Cons of

Retatrutide is currently in Phase 3 clinical trials, with seven additional trials expected to report results in 2026

But the potential is very exciting

Iwasaki, T., Miyazaki, W., Takeshita, A., Kuroda, Y

On 29 January 2026, the MHRA updated product information for GLP-1s and issued a drug safety alert to highlight that acute pancreatitis is a known but infrequent side effect that can be fatal, stressing that patients and clinicians should be alert to initial symptoms, such as severe, persistent stomach pain that may radiate to the back and may be accompanied by nausea and vomiting 26

While the juice can be a refreshing choice, there are some drawbacks

Zepbound (weekly injection tirzepatide) GIP/GLP-1 agonist ** Weight management for obesity (body mass index [BMI] 30) or overweight (BMI 27) plus at least one weight-related comorbidity such as hypertension, type 2 diabetes, and high cholesterol